Benefit or toxicity from neurologically targeted antiretroviral therapy?

Clinical Infectious Diseases

Volumn 50, Issue 6, 2010, Pages 930-932

  Brew, Bruce J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DARUNAVIR; EMTRICITABINE; INDINAVIR; LOPINAVIR; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

BRAIN FUNCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NOTE; PRIORITY JOURNAL;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; BRAIN CHEMISTRY; HIV INFECTIONS; HUMANS; NEUROPSYCHOLOGICAL TESTS;

EID: 77749277071     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650744     Document Type: Note

References (26)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HTV-associated neurocognitive disorders (HAND). Neurology 2007;69(18):1789-1799. (Pubitemid 350059308)
2. Brew BJ. AIDS dementia complex. In: Berger J, Portegies P, eds. AIDS/HIV and the nervous system: handbook of clinical neurology. Vol.85. Amsterdam: Elsevier Press, 2007:79-92.
3. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63(11 ):2084-2090.
4. Cysique LJA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV infected HAART-treatcd patients. Neurology 2006;66:1447-1450. (Pubitemid 43739663)
5. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21(14):1915-1921. (Pubitemid 47329768)
6. Wilkie FL, Goodkin K, Eisdorfer C, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosa 1998;10(2):125-132. (Pubitemid 28241360)
7. Albert SM, Marder K, Dooneief G, et al. Neuropsychologic impairment in early HPV infection: a risk factor for work disability. Arch Neurol 1995;52(5):525-530.
8. Marcotte TD, Heaton RK, Wolfson T, et al. The impact of HIV-related neuropsychological dysfunction on driving behavior. J Int Neuropsychol Soc 1999;5(7):579-592. (Pubitemid 30047684)
9. Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol 2009;4(2):163-174.
10. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002; 59(12): 1944-1950.
11. Bangsberg DR, Moss AR, Decks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004;53(5):696-699. (Pubitemid 38660267)
12. Grant I. Neurocognitive disturbances in HPV. Int Rev Psychiatry 2008; 20(1 )33-47.
13. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. Published 7 December 2009. doi:10.1097/ QAD.0b013e3283354a7b.
14. McCombe JA, Auer RN, Maingat FG, et al. Neurologic immune reconstitution inflam- matory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 2009;72(9):835-841.
15. Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007;48(3-4):166-172. (Pubitemid 46536084)
16. Piccinini M, Rinaudo MT, Anselmino A, et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antiviral Therapy 2005; 10(2):215-223. (Pubitemid 41151027)
17. Schweinsburg BC, Taylor MJ, Alhassoon OM, et al. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005; 11 (4): 356-364.
18. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23(11):1359-1366.
19. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002; 16 (9):595-609. (Pubitemid 34941127)
20. McGce B, Smith N, Awceka F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 2006; 7(3): 142-153. (Pubitemid 44309004)
21. Yilmaz A, Gisslén M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLOS One 2009;4(9):e6877.
22. Yilmaz A, Izadkhashti A, Price RW, et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009; 25(4): 457-461.
23. Yilmaz A, Watson V, Else L, Gisslén M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009;23(18): 2537-2540.
24. Winston A, Duncombe C, Li PCK, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV1-infccted individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010;50:920-929 (in this issue).
25. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65(l):65-70.
26. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIVassociated neurocognitive disorders. J Acquir Immune Defic Syndr 2009;52(l):56-63.